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Abstract
Background: Nonsteroidal anti-inflammatory drugs (NSAID) use may protect against Alzheimer's
disease (AD) risk. We sought examine the association between NSAID use and risk of AD, and
potential effect modification by APOE-ε4 carrier status and ethnicity.
Methods: The MIRAGE Study is a multi-center family study of genetic and environmental risk
factors for AD. Subjects comprised 691 AD patients (probands) and 973 family members enrolled
at 15 research centers between 1996 and 2002. The primary independent and dependent variables
were prior NSAID use and AD case status, respectively. We stratified the dataset in order to
evaluate whether the association between NSAID use and AD was similar in APOE-ε4 carriers and
non-carriers. Ethnicity was similarly examined as an effect modifier.
Results: NSAID use was less frequent in cases compared to controls in the overall sample
(adjusted OR = 0.64; 95% CI = 0.38–1.05). The benefit of NSAID use appeared more pronounced
among APOE-ε4 carriers (adjusted OR = 0.49; 95% CI = 0.24–0.98) compared to non-carriers,
although this association was not statistically significant. The pattern of association was similar in
Caucasian and African Americans.
Conclusions: NSAID use is inversely associated with AD and may be modified by APOE genotype.
Prospective studies and clinical trials of sufficient power to detect effect modification by APOE-ε4
carrier status are needed.
Background
Several cross-sectional [1,2], case-control [3-6], and pro-
spective studies [7-9] have reported an inverse association
between nonsteroidal anti-inflammatory drug (NSAID)
use and the risk of Alzheimer's disease (AD), whereas oth-
ers [10-12] have not. In this report, we present results of
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analyses of data from the Multi-Institutional Research in
Alzheimer's Genetic Epidemiology (MIRAGE) Study in
which we examined potential effect modification by
APOE-ε4 carrier status and ethnicity on this association.
Methods
Subjects and data collection
The MIRAGE Study is a multi-center family study of
genetic and environmental risk factors for AD sponsored
by the National Institute on Aging since 1991. The details
of MIRAGE Study data collection procedures, protocols
for obtaining family histories, and reports of validity stud-
ies of the MIRAGE questionnaires have been published
elsewhere. [13-15] Briefly, families were recruited through
probands meeting NINCDS-ADRDA criteria [16] for
probable or definite AD who were ascertained through
research registries and memory clinics. After obtaining
informed consent from non-demented family members,
and a combination of consent or assent – along with
informed consent by proxy – on living demented subjects,
questions eliciting demographic data and information
about presumptive risk factors for AD were obtained using
standardized MIRAGE questionnaires.
Questions pertaining to NSAID use were added to the
questionnaire in 1996, and the data presented in this
report were collected from May, 1996 through May, 2002.
Questions about the proband were answered by a surro-
gate source within the family, typically the spouse or adult
offspring. The same information was sought on non-
demented first-degree family members of these probands
over 50 years of age, usually a sibling or spouse (less com-
monly parents or children).
1020 family members in this analysis claimed to be cog-
nitively normal, or were reported by family informants to
be dementia-free. Of these, 982 were evaluated using the
modified Telephone Interview of Cognitive Status
(mTICS) [17,18], and normal cognitive status was con-
firmed in 973 (99.1%). Information on both patients and
first-degree family members was supplemented where
available by multiple informants, and medical and nurs-
ing home records.
To elicit information on prior NSAID use, the following
question was asked: "Have you ever taken a nonsteroidal
anti-inflammatory medication (e.g. Advil, Motrin, etc.) on
a daily basis for more than 6 months?" No distinction was
made between aspirin and other classes of NSAIDs. For
proxy reporting about a relative with AD, the question
substituted "your relative" for "you". For any affirmative
answer, a follow-up question asked for the dates at which
the medications were first used and the names of all
NSAIDs that had been used.
A discrete "index date" was established within each family
corresponding to the earliest date that the family or med-
ical records reported AD symptoms to have begun in the
proband. Subjects from each family (whether AD cases or
non-demented family members) were considered to have
been exposed to NSAIDs only if the starting date for
NSAID use preceded this index date by at least one year.
Age represented the age of cases and of non-demented rel-
atives at the index date, and was treated as a continuous
variable.
As shown in Figure 1, there were 756 probands and 1020
relatives over the age of 50 with APOE genotype who were
queried about prior NSAID use. After exclusions for those
subjects who had missing or unsure responses for the
name of their medication, did not include a medication
start date, or had missing data for the variables age, sex,
education or ethnicity, there remained for analysis 682
probands and 982 relatives. Of the 982 relatives, nine
were reported to be demented with the onset of their
dementia prior to the index date for that family, and their
diagnoses were verified by review of medical records as
having probable or definite AD by research criteria, so
these were classified with the probands as having AD.
Statistical analysis
Analyses were performed using SAS version 8.2. The pri-
mary independent and dependent variables were prior
NSAID use and AD case status, respectively. Crude odds
ratios were computed in the first instance, followed by
adjusted estimates using generalized estimating equation
(GEE) models [19] to account for the possibility that var-
iables of interest (e.g., medication use, APOE status) could
be correlated among individuals within families. Adjust-
ments were made for the following covariates: age, sex,
ethnicity (categorized as White, African-American, or
other), education (less than versus equal to or greater than
high school level), and APOE-ε4 carrier status (one or two
ε4 alleles vs. none).
We stratified the dataset in order to evaluate whether the
association between NSAID use and AD was similar in
APOE-ε4 carriers and non-carriers. In addition, we for-
mally evaluated these associations by adding an interac-
tion term (ε4 * NSAID use) to the GEE model. Ethnicity
was similarly examined as an effect modifier.
Results
Characteristics of the 1664 subjects are listed in Table 1.
AD patients were more likely to be older and to be APOE-
ε4 carriers compared to controls. The distributions of sex
and education were not different between cases and
controls.BMC Geriatrics 2005, 5:2 http://www.biomedcentral.com/1471-2318/5/2
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MIRAGE subjects ≥ 50 years (adjusted for family index date) with APOE genotype who completed the personal history  questionnaire Figure 1
MIRAGE subjects ≥ 50 years (adjusted for family index date) with APOE genotype who completed the personal history 
questionnaire.BMC Geriatrics 2005, 5:2 http://www.biomedcentral.com/1471-2318/5/2
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Sixty-six out of 973 non-demented relatives (6.8%) and
24 of 691 cases (3.5%) reported previous NSAID use
(odds ratio = 0.49; 95% CI = 0.31–0.80). After adjustment
for age, sex, educational level, and ethnicity, the odds
ratio (OR) of NSAID use among AD cases compared to
non-users was 0.57 (95% CI = 0.35–0.93); it was 0.64
(95% CI = 0.38–1.05) when APOE carrier status was
added to the GEE model (see Table 2).
The magnitude of inverse association was greater among
APOE ε4 carriers (OR = 0.49; 95% CI = 0.24–0.98) than
non-carriers (OR = 0.78; 95% CI = 0.39–1.52). However,
formal evaluation of the interaction between NSAID use
and APOE-ε4 carrier status did not reveal a significant dif-
ference (p = 0.40). The association between NSAID use
and AD risk was similar among Caucasian and African
Americans (data not shown).
Discussion
This study supports the findings of previous reports [1-6]
suggesting that use of NSAIDs for at least six months is
associated with a reduced risk of AD. This association
appears to be more robust among APOE-ε4 carriers than
non-carriers, although the difference in associations
between these two groups was not statistically significant.
The MIRAGE Study includes the largest number of well-
characterized AD cases and family controls to date, and
this large sample size permits adjustment for important
potential confounders, as well as the power to examine
effect modification by APOE genotype and ethnicity. The
subjects without dementia were first-degree family mem-
bers of AD cases, providing some degree of informal
matching on age, socioeconomic status, and health-seek-
ing behavior.
However, these results must be interpreted in light of
some methodological limitations. Data on NSAID use
Table 1: Characteristics of AD patients and non-demented family
CHARACTERISTIC AD (N = 691) NON DEMENTED 
(N = 973)
AGE ADJUSTED 
PERCENT AD
AGE ADJUSTED 
PERCENT NON-
DEMENTED
P-VALUE*
Mean Age (SD) 70.0 (8.2) 65.0 (8.8) <0.0001
Sex (%male) 242 (35.0) 381 (39.2) 36.5 39.9 0.39
Greater than HS Ed (%) 403 (58.3) 643 (66.1) 59.3 65.1 0.10
African American (%) 215 (31.1) 204 (21.0) 28.4 21.3 0.01
Use of NSAIDs† (%) 24 (3.5) 66 (6.8) 3.5 6.7 0.08
APOE-ε4 carrier (%) 448 (64.8) 370 (38.0) 65.3 38.0 <0.0001
* Reported p-values use General Estimating Equations to account for correlation among observations.
†Exposure to non-steroidal anti-inflammatory drugs had to precede index date by one year or more.
Table 2: Risk of AD with and without prior use of NSAIDs, stratified by APOE-ε4 carrier status
EXPOSURE AD (N = 691) NON-DEMENTED 
FAMILY MEMBERS (N 
= 973)
CRUDE ODDS 
RATIO (95% CI)
AGE-ADJUSTED 
ODDS RATIO (95% 
CI)
ADJUSTED ODDS 
RATIO (95% CI)
Overall
No NSAIDs 667 907 1.0 1.0 1.0
Use of NSAIDs 24 66 0.49 (0.31, 0.80) 0.55 (0.34, 0.88) 0.64 (0.38, 1.05)*
Having no ε4 alleles
No NSAIDs 231 556 1.0 1.0 1.0
Use of NSAIDs 12 47 0.61 (0.32, 1.18) 0.75 (0.38, 1.46) 0.78 (0.39, 1.52)**
Having at least one ε4 allele
No NSAIDs 436 351 1.0 1.0 1.0
Use of NSAIDs 12 19 0.51 (0.24, 1.06) 0.47 (0.24, 0.96) 0.49 (0.24, 0.98)**
*Adjusted for age, sex, ethnicity, education, and APOE-ε4 status.
**Adjusted for age, sex, ethnicity, and education.
***NSAID*APOE-ε4 interaction p-value = 0.04.BMC Geriatrics 2005, 5:2 http://www.biomedcentral.com/1471-2318/5/2
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was collected with a single retrospective question that did
not distinguish between aspirin use and non-aspirin
NSAID use. Moreover, while non-demented participants
reported on themselves, a proxy historian reported on
most of the demented individuals.
Differential reporting is a potential source of bias in a
study that uses self-report on most of the non-demented
subjects, yet relies on surrogate respondents for all of the
subjects with AD. Asymmetric data collection is difficult
to avoid when cases are cognitively impaired, but may be
more accurate than expected in AD patients where the sur-
rogate historian has a long association with the subject.
We addressed this potential bias by performing an inde-
pendent validation study to determine the accuracy of sur-
rogate information on a number of questions, including
the same questions used in this report about NSAID use.
[15] This study found substantial reliability on the NSAID
item (kappa = 0.70). While a validation study comparing
proxy historians for non-demented persons does not per-
fectly mirror the situation in which proxy historians
report on demented individuals, our study revealed excel-
lent concordance for surrogate responses from most cate-
gories of relatives.
This result is consistent with those of prior studies which
found a similar association despite differences in study
design (cross-sectional [1,2] vs. case-control [3-6,10,11]
vs. prospective [7-9,12]), sampling frame (family mem-
bers [10] vs. registry-based [11] vs. general population [1-
9,12]), ascertainment of exposure, type of medication
considered (aspirin [2-4,6,8-10,12] vs. non-aspirin
NSAIDs [1-11] vs. 'any' NSAID [4,8]), duration of expo-
sure (current [1-3] vs. any history of use, duration ranging
from a week to at least six months [3,5-12]), and degree of
matching or adjustment (usually adjusted for age, sex, and
education, less frequently APOE genotype [7-9,12]).
While many studies have examined the association
between NSAID use and risk of AD, few have examined
the impact of APOE genotype on this association. The
Cache County Study [9,20], the Canadian Study for
Health and Aging (CSHA) [8], and the Rotterdam Study
[7] adjusted for APOE and tested for effect modification
and found none. But they had fewer AD cases, and, in the
CSHA had a smaller proportion of genotyped subjects.
The Rotterdam Study [7] reported separate odds ratios for
APOE-ε4 carriers and non-carriers, but this sample did not
have any subjects who were both APOE-ε4 carriers and
who reported long-term use of NSAIDs. They found no
difference in risk between those with at least one ε4 allele
compared to ε4 non-carriers among subjects who used
NSAIDs between one month and two years.
Our data suggest an enhanced protective benefit of NSAID
use among those with ε4. A smaller protective effect was
also evident among those lacking ε4. In our sample there
were relatively few AD cases who were not ε4 carriers, thus
the appearance of different patterns of association
between NSAID use and AD risk among APOE genotype
subgroups may be spurious. This difference could also
have arisen as a result of bias and confounding. The gen-
otype-specific association could be explained by differen-
tial inclusion of subjects into the study on the basis of
APOE-ε4 carrier status and NSAID use. This might occur if
there were differential mortality, according to APOE gen-
otype, among those with AD who had a history of NSAID
use; or if for any reason among NSAID users APOE-ε4 car-
riers were less likely than non-carriers to be diagnosed
with AD (or conversely, if among non-users of NSAIDs
AD was more likely diagnosed in APOE-ε4 carriers com-
pared to non-carriers). Differential recall could also give
rise to this observation. However, these explanations are
unlikely because subjects were not selected on the basis of
APOE genotype. It is also possible that APOE-ε4 carrier
status is a proxy for differentially distributed unmeasured
confounders related to NSAID use such as inflammatory
disease processes.
Alternatively, our results imply that NSAID use affects AD
risk differently between APOE-ε4 carriers and non-carri-
ers. For example, because ε4 carriers are inherently more
vulnerable to AD, there is a greater opportunity for attrib-
utable risk reduction. This explanation does not imply
biological interaction between NSAIDs and ε4. On the
other hand, the ε4 isoform may have greater pro-inflam-
matory properties [21] and ε4 individuals may be more
responsive to the benefits of NSAID use than those lacking
ε4.
Examination of this finding in prospective studies and
clinical trials of sufficient power (such as the ADAPT
Study [22], a prospective trial of anti-inflammatory use in
the prevention of AD) to detect effect modification by
APOE-ε4 carrier status is needed. Such confirmation
would provide critical insights into the mechanisms by
which APOE isoforms modulate AD risk and into novel
therapeutic strategies.
Conclusions
NSAID use is inversely associated with AD and may be
modified by APOE genotype. Prospective studies and clin-
ical trials of sufficient power to detect effect modification
by APOE-ε4 carrier status are needed.
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